Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Results of comparison study favor exemestane for advanced disease
April 6th, 2004
The first results from the only Phase III trial to compare tamoxifen with the newer hormone treatment exemestane in advanced breast cancer shows that exemestane is safe, superior, and lengthens progression-free survival. The median progression-free survival for patients taking exemestane (Pfizer brand name, Aromasin) was 10.9 months compared with 6.7 months for those taking tamoxifen. Complete and partial response rates were also higher in the exemestane arm with 7.4% responding completely and 36.8% partially, compared with 2.6% of tamoxifen patients completely responding and 26.6% partially responding. Robert Paridaens MD, told delegates at the 4th...
Source: Cancer Weekly (2004-04-06)
|
